Condition: GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor · Gastroenteropancreatic Neuroendocrine Tumor Disease · Sponsor: RayzeBio, Inc.
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
This description comes directly from the study's public registry record.
RayzeBio Clinical Trials · +1 619 657 0057 · clinicaltrials@rayzebio.com
Always discuss trial participation with your own doctor first.
| Research Facility | Iowa City, Iowa, United States | Recruiting |
| Research Facility | Lexington, Kentucky, United States | Recruiting |
| Research Facility | St Louis, Missouri, United States | Recruiting |
| Research Facility | St Louis, Missouri, United States | Recruiting |
| Research Facility | Columbus, Ohio, United States | Recruiting |
| Research Facility | Nashville, Tennessee, United States | Recruiting |
| Research Facility | Salt Lake City, Utah, United States | Recruiting |
| Research Facility | Toronto, Ontario, Canada | Recruiting |
| Research Facility | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07165132